2021 年 4 月洛杉矶县成年人中针对 SARS-CoV-2 受体结合域的抗体血清阳性率和疫苗接种率：洛杉矶大流行监测队列研究。
Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.
机构信息
Sol Price School of Public Policy, University of Southern California, Los Angeles.
Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles.
出版信息
JAMA Netw Open. 2022 Jan 4;5(1):e2144258. doi: 10.1001/jamanetworkopen.2021.44258.
Abstract
This cross-sectional study estimates the seroprevalence of antibodies specific to the receptor binding domain of the spike protein of SARS-CoV-2 and vaccination coverage among adults in Los Angeles County, California, in April 2021.
摘要
本横断面研究估计了 2021 年 4 月加利福尼亚州洛杉矶县成年人中针对 SARS-CoV-2 刺突蛋白受体结合域的特异性抗体血清阳性率和疫苗接种率。
相似文献
1
Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study.
JAMA Netw Open. 2022 Jan 4;5(1):e2144258. doi: 10.1001/jamanetworkopen.2021.44258.
2
Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.
JAMA. 2020 Jun 16;323(23):2425-2427. doi: 10.1001/jama.2020.8279.
3
Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
Microbiol Spectr. 2022 Feb 23;10(1):e0256321. doi: 10.1128/spectrum.02563-21.
4
Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system.
PLoS One. 2024 Jun 20;19(6):e0303303. doi: 10.1371/journal.pone.0303303. eCollection 2024.
5
Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts.
mSphere. 2021 Apr 21;6(2):e00224-21. doi: 10.1128/mSphere.00224-21.
6
The Second Round of a Population-Based Seroprevalence Study of Anti-SARS-CoV-2 Antibodies and COVID-19 Vaccination Assessment in the Republika Srpska, Bosnia and Herzegovina.
Influenza Other Respir Viruses. 2025 Jan;19(1):e70053. doi: 10.1111/irv.70053.
7
Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
Lancet. 2021 Mar 20;397(10279):1075-1084. doi: 10.1016/S0140-6736(21)00238-5.
8
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.
BMC Infect Dis. 2024 Aug 20;24(1):841. doi: 10.1186/s12879-024-09670-w.
9
Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.
EBioMedicine. 2021 Aug;70:103495. doi: 10.1016/j.ebiom.2021.103495. Epub 2021 Jul 23.
10
SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Front Immunol. 2021 Sep 27;12:728021. doi: 10.3389/fimmu.2021.728021. eCollection 2021.
引用本文的文献
1
The association between baseline physical and mental health and the risk of postacute sequelae of COVID-19 infection.
Sci Rep. 2025 Jul 8;15(1):24374. doi: 10.1038/s41598-025-09676-7.
2
Prevalence of SARS-CoV-2 infection and immunity in a New York county in 2022 reveals frequent asymptomatic or undiagnosed infections.
PLoS One. 2025 May 28;20(5):e0323659. doi: 10.1371/journal.pone.0323659. eCollection 2025.
3
The differential impacts of COVID-19 mortality on mental health by residential geographic regions: The Los Angeles Pandemic Surveillance Cohort Study.
PLoS One. 2024 Jul 9;19(7):e0304779. doi: 10.1371/journal.pone.0304779. eCollection 2024.
4
Anti-SARS-CoV-2 Antibody Response Among Spectators of Amir Cup 2020 With a History of Recovery From COVID-19 in Qatar: A Historic Cohort Study.
Cureus. 2024 Feb 18;16(2):e54406. doi: 10.7759/cureus.54406. eCollection 2024 Feb.
5
Association between levels of receptor binding domain antibodies of SARS-CoV-2, receipt of booster and risk of breakthrough infections: LA pandemic surveillance cohort study.
Sci Rep. 2023 Nov 25;13(1):20761. doi: 10.1038/s41598-023-47261-y.
6
Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.
Euro Surveill. 2023 May;28(21). doi: 10.2807/1560-7917.ES.2023.28.21.2200809.
7
Quantification of Severe Acute Respiratory Syndrome Coronavirus 2 Binding Antibody Levels To Assess Infection and Vaccine-Induced Immunity Using WHO Standards.
Microbiol Spectr. 2023 Feb 14;11(1):e0370922. doi: 10.1128/spectrum.03709-22. Epub 2023 Jan 23.
8
Factors associated with parents' willingness to vaccinate their children against COVID-19: The LA pandemic surveillance cohort study.
AIMS Public Health. 2022 May 25;9(3):482-489. doi: 10.3934/publichealth.2022033. eCollection 2022.
9
Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.
Vaccines (Basel). 2022 Oct 5;10(10):1663. doi: 10.3390/vaccines10101663.
10
SARS-CoV-2 Seroepidemiological Investigation in Jordan: Seroprevalence, Herd Immunity, and Vaccination Coverage. A Population-Based National Study.
Int J Gen Med. 2022 Sep 5;15:7053-7062. doi: 10.2147/IJGM.S371711. eCollection 2022.
本文引用的文献
1
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
2
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection.
JAMA Intern Med. 2021 May 1;181(5):672-679. doi: 10.1001/jamainternmed.2021.0366.
3
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
4
Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.
J Virol Methods. 2021 Feb;288:114025. doi: 10.1016/j.jviromet.2020.114025. Epub 2020 Nov 20.
5
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
Sci Immunol. 2020 Jun 11;5(48). doi: 10.1126/sciimmunol.abc8413.
6
Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.
JAMA. 2020 Jun 16;323(23):2425-2427. doi: 10.1001/jama.2020.8279.
Zotero 插件